Ananda Developments PLC Appointment of AQSE Corporate Adviser and Broker (1527Z)
May 15 2023 - 2:00AM
UK Regulatory
TIDMANA
RNS Number : 1527Z
Ananda Developments PLC
15 May 2023
12 May 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Appointment of AQSE Corporate Adviser and Broker
Following the completion of the acquisition of MRX Global
Limited and its wholly owned subsidiary MRX Medical Limited and
raising of GBP427,400, the directors of Ananda are pleased to
announce that SP Angel Corporate Finance LLP ("SP Angel") has been
appointed as the Company's AQSE Corporate Adviser and sole Broker,
with immediate effect.
SP Angel has a dedicated in-house healthcare research team and
will release an Initiation Research Report on the Company in the
coming weeks. As SP Angel acts as a NOMAD it would be able to
support Ananda with a smooth transition to AIM at the appropriate
time.
Ananda's CEO, Melissa Sturgess, commented: "Ananda's ambition to
be a provider of cannabis-based medicines for the treatment of
complex, chronic inflammatory pain conditions, places us firmly in
the healthcare sector. We believe that working with the dedicated,
experienced, and respected healthcare research and capital markets
team at SP Angel will help us refine our story, expand our reach to
a wider audience and prepare the company for bigger markets. I
would also like to take this opportunity, on behalf of the Board,
to thank Peterhouse for its support and guidance as our corporate
adviser and broker since Ananda's listing in 2018."
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Chief Operating Officer
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE
LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company whose ambition
is to be a leading provider of high-quality medical cannabis for
the treatment of complex, chronic inflammatory pain conditions for
the UK and international markets.
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXMZGMKDMFGFZM
(END) Dow Jones Newswires
May 15, 2023 02:00 ET (06:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jul 2023 to Jul 2024